The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Two healthcare innovators, MiniMed Group, Inc. (NASDAQ:MMED) and Abbott Laboratories (NYSE:ABT), hit the spotlight this August with a milestone partnership. On August 17, MiniMed announced that its MiniMed Flex system is commercially shipping in the U.S., integrated with Abbott's Instinct continuous glucose sensor. This collaboration marks a major leap in diabetes tech, pairing MiniMed's smallest, only app-controlled automated insulin delivery system with Abbott's world's-smallest 15-day sensor. Driven by SmartGuard technology and Meal Detection automation, the setup holds 300 units of insulin, connects to a 7-day Extended infusion set, and delivers proven clinical results, reaching 80% Time in Range and over 90% overnight in real-world data. While this product integration unites their ecosystems, a look into their financials reveals two very different financial profiles.

Abbott operates as a mega-cap healthcare powerhouse. In its Q2 2026 earnings, Abbott Laboratories (NYSE:ABT) reported $12.6 billion in quarterly revenue, reflecting a 13.0% reported growth rate, and delivered $1.31 in adjusted EPS. Buoyed by robust medical device performance and double-digit electrophysiology growth, Abbott reaffirmed its 6.5%–7.5% organic sales target and raised full-year EPS guidance to $5.45–$5.60.

By contrast, MiniMed Group, Inc. (NASDAQ:MMED) operates as a specialized pure-play diabetes tech company with a market cap of roughly $5.67 billion. Scheduled to report its fiscal Q1 2027 results on September 1, 2026, MiniMed brings pure-play agility and targeted innovation to the table. Financially, Abbott is comfortably doing better in absolute scale, revenue velocity, profitability, and balance sheet strength. Abbott's broad diversification across diagnostics, nutrition, and medical devices insulates it from single-product headwinds, whereas MiniMed represents a higher-risk, high-reward pure-play on automated insulin delivery adoption.

For MiniMed, the bull case rests on market share gains from the MiniMed Flex launch, where pairing Abbott's top-tier Instinct sensor solves a historical weakness in sensor ergonomics. The bear case centers on its execution risk and intense competition from larger medtech rivals that could squeeze MiniMed's margins.

For Abbott, the bull case lies in its massive free cash flow, relentless multi-sector innovation (like the Libre Duo biowearable), and consistent earnings expansion. The bear case highlights sluggish growth in traditional sub-segments like pediatric nutrition and macro pressures in international markets.

Institutional smart money heavily favors Abbott's structural stability. In Q1 2026, 73 hedge funds held Abbott shares, up from 71 in Q4 2025, backed by massive conviction moves like Arrowstreet Capital (10.9 million shares worth $988.8M, +98%) and Citadel Investment Group (8.6 million shares worth $780.1M, +349%).

MiniMed saw a speculative uptick, growing from 0 fund holdings in Q4 2025 to 22 in Q1 2026, signaling emerging institutional interest, but at a fraction of Abbott's widespread adoption.

While Abbott wins on financial execution and earnings safety, MiniMed Group, Inc. (NASDAQ:MMED) gains a vital commercial catalyst through this hardware synthesis. Moving forward, investors should watch MiniMed's September 1 fiscal Q1 earnings call for initial U.S. adoption rates and order pull-through on the Flex-Instinct rollout. For Abbott Laboratories (NYSE:ABT), investors must track whether sensor supply partnerships translate into accelerated, high-margin Medical Device segment revenue through late 2026.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.